Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

Peter Vaupel; Jürgen Dunst; Andreas Engert; Joachim Fandrey; Petra Feyer; Mathias Freund; Wolfgang Jelkmann

doi:10.1159/000084033

Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

Peter Vaupel^*, Jürgen Dunst, Andreas Engert, Joachim Fandrey, Petra Feyer, Mathias Freund, Wolfgang Jelkmann

^*Corresponding author for this work

23 Citations (Scopus)

Abstract

It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

Original language	English
Journal	Onkologie
Volume	28
Issue number	4
Pages (from-to)	216-221
Number of pages	6
ISSN	0378-584X
DOIs	https://doi.org/10.1159/000084033
Publication status	Published - 04.2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000084033

Cite this

@article{82133bc5f13543a08eea82a9478460d4,

title = "Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia",

abstract = "It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).",

author = "Peter Vaupel and J{\"u}rgen Dunst and Andreas Engert and Joachim Fandrey and Petra Feyer and Mathias Freund and Wolfgang Jelkmann",

year = "2005",

month = apr,

doi = "10.1159/000084033",

language = "English",

volume = "28",

pages = "216--221",

journal = "Onkologie",

issn = "0378-584X",

number = "4",

}

TY - JOUR

T1 - Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

AU - Vaupel, Peter

AU - Dunst, Jürgen

AU - Engert, Andreas

AU - Fandrey, Joachim

AU - Feyer, Petra

AU - Freund, Mathias

AU - Jelkmann, Wolfgang

PY - 2005/4

Y1 - 2005/4

N2 - It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

AB - It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

UR - http://www.scopus.com/inward/record.url?scp=20844442466&partnerID=8YFLogxK

U2 - 10.1159/000084033

DO - 10.1159/000084033

M3 - Scientific review articles

C2 - 15840971

AN - SCOPUS:20844442466

SN - 0378-584X

VL - 28

SP - 216

EP - 221

JO - Onkologie

JF - Onkologie

IS - 4

ER -

Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this